MICHAEL SINFUEGO: Open Payments
NPI 1174235451 · MISSION HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 27 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $289 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 10 | $169 |
| AstraZeneca Pharmaceuticals LP | 6 | $143 |
| Novo Nordisk Inc | 2 | $47 |
| Calliditas Therapeutics US Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $23 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $20 |
Products named: LOKELMA, KRYSTEXXA, Ozempic, TARPEYO, Yorvipath, PURIFIED CORTROPHIN GEL, REPATHA, JARDIANCE.
Industry payments across CA — which companies pay providers there.
